Saturday 17 October 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024. In the quarter to June 2026, revenue fell 34.6%, EPS grew 78.1% and free cash flow fell 22.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.67
0.03
+4.69%
Follow COCH
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 3 | 3 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (133.76) | (49.48) | (39.37) | (60.12) |
P/S ratio |
— | — | — | 0.00 | 73.54 | 119.42 | 63.70 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (314.33) | (116.36) | (91.54) | (141.53) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (42.64) | (2.09) | (5.28) | (2.70) |
P/B ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | 174.39 | 190.19 | 175.25 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (15.46) | (3.22) | (2.38) | (2.32) |
EV/FCF |
— | — | — | (15.46) | (3.20) | (2.26) | (2.30) |
Quick Ratio |
— | 0.26 | 0.06 | 0.09 | 0.61 | 0.84 | 0.33 |
Current Ratio |
— | 0.26 | 0.32 | 0.65 | 1.02 | 1.18 | 0.54 |
Net Debt/EBITDA |
— | 35.71 | 0.03 | (3.85) | 0.24 | (0.73) | 0.18 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1,306.61% | 0.00% | 162.21% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | (0.92) | 0.00 | (0.99) | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 | 0.02 |
Operating CF/Net income |
— | 0.00 | 12.88 | 0.55 | 0.55 | 0.64 | 0.64 |
Capex/Depreciation |
— | 0.00 | 0.00 | (2.91) | (0.21) | (0.80) | (0.14) |
Interest Coverage |
— | — | (138.06) | (1.42) | — | (23.60) | (14.01) |
| — | 0.00% | 1.37% | 43.68% | 164.71% | 271.35% | 184.92% | |
| — | (1.17%) | (0.12%) | (7.42%) | (577.65%) | (282.43%) | (285.25%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 0.99% | 13.86% | 2,948.70% | (5,990.61%) | (1,062.40%) | 674.72% |
Average Days of Receivables |
— | — | — | 63.14 | 284.15 | 1,326.98 | 80.27 |
Research and Development Expense of Revenue |
— | 0.00% | — | 2,099.16% | 2,834.18% | 4,524.00% | 5,180.91% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 1,464.14% | 2,825.95% | 3,804.44% | 3,797.10% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 498.42% | 249.78% | 309.13% |
Graham Net Nets |
— | — | — | (0.37) | (0.11) | (0.80) | (0.94) |
Graham Number |
— | — | — | 11.25 | 2.83 | 5.64 | 3.79 |
Earnings Yield |
— | — | — | (15.70%) | (129.98%) | (98.60%) | (184.85%) |
Free Cash Flow Yield |
— | — | — | (8.68%) | (74.21%) | (70.52%) | (119.73%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 |
Operating CF per Share |
— | 0.00 | (0.31) | (0.87) | (1.39) | (0.96) | (0.78) |
Capex per Share |
— | 0.00 | 0.00 | (0.02) | (0.01) | (0.05) | (0.01) |
Free Cash Flow per Share |
— | 0.00 | (0.31) | (0.89) | (1.40) | (1.01) | (0.79) |
Cash per Share |
— | 0.00 | 0.01 | 0.02 | 0.34 | 0.29 | 0.16 |
Shareholders Equity per Share |
— | 0.00 | (3.47) | (3.58) | (0.14) | (1.00) | (0.52) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (3.47) | (3.58) | (0.14) | (1.00) | (0.52) |
Free Cash Flow |
— | 0.00 | (3.24) | (9.02) | (17.24) | (18.93) | (18.38) |
Working Capital |
— | (0.07) | (1.81) | (0.87) | 0.17 | 1.36 | (5.28) |
Capital Expenditures |
— | 0.00 | — | (0.22) | (0.15) | (0.98) | (0.18) |
Net Current Asset Value |
— | (0.07) | (462.75) | (37.10) | (2.59) | (21.48) | (14.44) |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | — | 0.92 | 0.48 | 4.36 | 0.74 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.23 | 2.09 | 0.96 | 1.22 |
Cash ROIC |
— | 0.00% | 8.86% | 345.05% | (706.14%) | (353.35%) | 218.32% |
Accounts Receivable Turnover |
— | — | — | 0.00 | 2.20 | 0.42 | 0.55 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.61 | 0.62 | 0.46 | 0.38 |
Inventory Turnover |
— | — | — | 0.00 | 0.58 | 0.48 | 0.54 |
Average Days of Payables |
— | 0.00 | 0.00 | 735.13 | 718.90 | 812.64 | 1,219.45 |
Days of Inventory on Hand |
— | — | — | 949.15 | 649.51 | 840.19 | 645.64 |
Average Receivables |
— | — | — | — | 0.14 | 0.53 | 0.44 |
Average Payables |
— | 0.36 | 0.36 | 0.81 | 1.28 | 1.60 | 2.29 |
Average Inventory |
— | — | — | — | 1.35 | 1.56 | 1.63 |
Average Assets |
— | 0.06 | 213.51 | 214.73 | 5.41 | 9.90 | 10.05 |
Average Common Equity |
— | 194.16 | (18.34) | (36.45) | (18.99) | (10.31) | (15.50) |
Columns are period end dates